Inactive Instrument

Intersect ENT, Inc.

Equities

XENT

US46071F1030

Medical Equipment, Supplies & Distribution

Faruqi & Faruqi, LLP : is Investigating Intersect ENT, Inc. (XENT) on Behalf of its Shareholders

June 18, 2018 at 12:12 pm EDT

NEW YORK, June 18, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential breaches of fiduciary duty by the board of directors at Intersect ENT, Inc. ("Intersect" or the "Company") (NASDAQ: XENT).

Faruqi & Faruqi, LLP. (PRNewsfoto/Faruqi & Faruqi, LLP)

Request more information now by clicking here: www.faruqilaw.com/XENT. There is no cost or obligation to you.

Take Action

If you currently own Intersect stock and would like to discuss your legal rights, please visit www.faruqilaw.com/XENT. You can also contact us by calling Nina Varindani at (212) 983-9330 or by sending an e-mail to nvarindani@faruqilaw.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding Intersect's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

CONTACT:
Nina M. Varindani
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
nvarindani@faruqilaw.com
Telephone: (212) 983-9330

View original content with multimedia:http://www.prnewswire.com/news-releases/faruqi--faruqi-llp-is-investigating-intersect-ent-inc-xent-on-behalf-of-its-shareholders-300667828.html

SOURCE Faruqi & Faruqi, LLP

Latest news about Intersect ENT, Inc.

Intersect ENT, Inc.(NasdaqGM:XENT) dropped from S&P Healthcare Equipment Select Industry Index	22-05-17	CI
Intersect ENT, Inc.(NasdaqGM:XENT) dropped from S&P TMI Index	22-05-17	CI
Intersect ENT, Inc.(NasdaqGM:XENT) dropped from S&P Global BMI Index	22-05-17	CI
Medtronic Completes Purchase Of US Medical Device Group Intersect ENT	22-05-13	MT
Medtronic Completes Purchase of Intersect ENT	22-05-13	MT
Intersect ENT, Inc.(NasdaqGM:XENT) dropped from NASDAQ Composite Index	22-05-13	CI
Hemostasis, LLC acquired Fiagon AG Medical Technologies from Intersect ENT, Inc.	22-05-12	CI
Medtronic plc completed the acquisition of Intersect ENT, Inc..	22-05-12	CI
Intersect ENT, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-04	CI
Intersect ENT, Inc. Enters into Amendment No.1 to Facility Agreement	22-04-18	CI
Intersect ENT, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-08	CI
Intersect ENT Reports Positive Data From Real-World Evidence Study of Propel Sinus Implants	22-01-25	MT
Intersect ENT®, Inc. Announces Positive Results of Observational	22-01-25	CI
Berenberg Bank Terminates Coverage on a Number of Companies Due to Analysts' Departures From the Firm	21-12-13	MT
Intersect ENT, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-02	CI
Earnings Flash (XENT) INTERSECT ENT Reports Q3 Loss $-0.48	21-11-02	MT
Earnings Flash (XENT) INTERSECT ENT Posts Q3 Revenue $24.4M	21-11-02	MT
Transcript : Intersect ENT, Inc. - Shareholder/Analyst Call	21-10-08
Intersect ENT, Inc. Enters into Facility Agreement	21-09-27	CI
North American Morning Briefing : Blockbuster -3-	21-08-13	DJ
INTERSECT ENT : SVB Leerink Downgrades Intersect ENT to Market Perform From Outperform; Price Target is $28.25	21-08-12	MT
North American Morning Briefing : Investors Await -3-	21-08-11	DJ
INTERSECT ENT : BTIG Downgrades Intersect ENT to Neutral From Buy	21-08-10	MT
INTERSECT ENT : Canaccord Genuity Downgrades Intersect ENT to Hold from Buy, Adjusts Price Target to $28.25 from $29	21-08-09	MT
INTERSECT ENT : Berenberg Bank Adjusts Intersect ENT Price Target to $28.25 From $18, Maintains Hold Rating	21-08-09	MT

Chart Intersect ENT, Inc.

Duration

Period

More charts

Company Profile

Intersect ENT, Inc. is a global ear, nose, and throat (ENT) medical technology company. The Company's steroid-releasing products are designed to provide mechanical spacing and deliver targeted therapy (mometasone furoate) to the site of disease. These products include its PROPEL family of products (PROPEL, PROPEL Mini and PROPEL Contour) and the SINUVA (mometasone furoate) Sinus Implant. The PROPEL family of products are used in adult patients to reduce inflammation and maintain patency following sinus surgery, primarily in hospitals and ambulatory surgery centers (ASC), with increasing applications in the physician office setting of care in conjunction with balloon dilation and following post-surgical debridement. SINUVA is a physician administered drug, designed to be used in the physician office setting of care to treat adult patients who have had ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps. It also offers ENT products, such as VenSure and CUBE.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
ABBOTT LABORATORIES	-4.36%	183B
MEDTRONIC PLC	-3.87%	105B
BECTON, DICKINSON AND COMPANY	-4.38%	67.36B
DEXCOM, INC.	+8.23%	51.77B
CENCORA, INC.	+15.54%	47.29B
HOYA CORPORATION	-1.73%	40.2B
WEST PHARMACEUTICAL SERVICES, INC.	+7.16%	27.62B
SARTORIUS STEDIM BIOTECH	-16.12%	21.75B
METTLER-TOLEDO INTERNATIONAL, INC.	-1.68%	25.51B

Other Medical Equipment, Supplies & Distribution